Abpro Corporation(ABP)Earnings, Financials & Key Ratios
ABP•NASDAQ
$0.52
Price updated Jun 20, 2026
AboutAbpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.Show more
- Revenue$183K+50.0%
- EBITDA-$9M+15.1%
- Net Income-$7M+38.2%
- EPS (Diluted)-23.10+38.4%
- Gross Margin100%
- EBITDA Margin-5081.42%+43.4%
- Operating Margin-5421.31%+43.7%
- Net Margin-3951.91%+58.8%
ABP Price & Volume
Abpro Corporation (ABP) stock price & volume — 10-year historical chart
Loading chart...
Abpro Corporation Faces Imminent Liquidity Insolvency Risk
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity insolvency risk
Key Thesis Takeaways
- Abpro Corporation exhibits a precarious financial profile characterized by negligible revenue generation and a persistent reliance on external capital to fund R&D operations.
- The company's structural inability to achieve operational scale, evidenced by quarterly losses frequently exceeding $2 million, suggests a high probability of further dilutive financing events.
- Investors should monitor the critical liquidity shortfall, as the current cash position of $343,000 against significant liabilities poses a severe threat to the company's ongoing clinical trial trajectory.
Verdict Logic
the company's current ratio of 0.07 and the rapid depletion of assets from $37.5 million in 2023Q3 to $1.7 million in 2025Q3 indicate an unsustainable path that necessitates immediate capital restructuring.
ABP Growth Metrics
Abpro Corporation (ABP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-35.85%
3 Years-27.49%
TTM50%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM15.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM58.67%
Return on Capital
10 Years-238.31%
5 Years-348.64%
3 Years-757.38%
Last Year-
Peers Comparison
Key metrics vs top competitors for Abpro Corporation (ABP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.52 | $163.53K | -0.02 | 50% | -3951.91% | — | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — | |
| $4.75 | $301.92M | -4.03 | 0.78% | -44.79% | -147.8% | — | |
| $15.67 | $1.15B | -12.64 | 13.65% | -185.71% | -28.77% | — |
Compare ABP vs Peers
Abpro Corporation (ABP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ABP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ABP Frequently Asked Questions
Abpro Corporation (ABP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Abpro Corporation's revenue?
Abpro Corporation (ABP) reported $0.2M in revenue for fiscal year 2024. This represents a 89% decrease from $1.7M in 2016.
How fast is Abpro Corporation growing?
Abpro Corporation (ABP) grew revenue by 50.0% over the past year. This is strong growth.
Is ABP profitable?
Abpro Corporation (ABP) reported a net loss of $14.0M for fiscal year 2024.
Dividend & Returns
What is Abpro Corporation's free cash flow?
Abpro Corporation (ABP) had negative free cash flow of $13.6M in fiscal year 2024, likely due to heavy capital investments.